Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan platform, reported first quarter 2026 results highlighted by accelerating clinical adoption. The company announced a 196% year-over-year increase in Nociscan scan volumes for Q1 2026 compared to Q1 2025, along with a 64% sequential growth from Q4 2025.
According to the company's press release, growth was driven by both new account activation and deeper utilization within existing sites, signaling increasing integration into clinical workflows. Repeat usage trends reinforce the value proposition for Nociscan and position Aclarion for sustained expansion. The opportunity for Nociscan remains significant: each year, approximately 5.8 million lumbar MRIs are performed in the U.S. for low back pain, representing a potential $2 billion market opportunity for technologies that can provide objective, data-driven evaluation of discogenic pain.
Key catalysts driving growth include reimbursement progress in the U.K., where Nociscan has been reimbursed for several months by Vitality, AXA, and Aviva—three of the four largest private insurers in the U.K. This early payer adoption provides meaningful validation and a pathway for broader coverage expansion. The company also launched a targeted direct-to-patient campaign in the U.K., featuring a new video with Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic.
On the clinical front, Aclarion is advancing the CLARITY randomized trial designed to validate the clinical utility of Nociscan in guiding treatment decisions. A preliminary internal readout is expected in the second half of 2026, with an expected public disclosure of early interim results in late 2026. Additionally, seven ongoing clinical trials and multiple investigator-initiated real world evidence trials are underway to support reimbursement discussions and potential local coverage decisions by commercial insurance carriers.
The company also strengthened its intellectual property portfolio with a newly issued patent covering use of AI in workflows of future products, which could accelerate the company's ability to scale and enhance already strong gross margins. Aclarion now holds 64 total issued and pending patents worldwide, strengthening its long-term competitive moat.
Financially, Aclarion enters this growth phase with a solid foundation. As of March 31, 2026, the company had $19.0 million in cash with no outstanding debt and a clean capital structure. There were 2,444,871 common shares outstanding as of March 31, 2026, and 2,882,371 on a fully diluted basis, representing approximately $6.60 per share in cash. The company also announced a $2.5 million share repurchase program this week. Based on current operating plans, management believes existing cash resources are sufficient to fund operations into the second half of 2027.
Brent Ness, Chief Executive Officer of Aclarion, commented: “Q1 represents a clear inflection for Aclarion. Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution with our recently hired Commercial Directors in the UK and the Eastern US. Importantly, we are still in the early stages of commercializing Nociscan into a large and underpenetrated market, with nearly 6 million lumbar MRIs performed annually in the U.S. alone. As adoption expands, Nociscan has the potential to address a multi-billion-dollar market opportunity.”
For more information, visit www.aclarion.com. The latest news and updates relating to $ACON are available in the company's newsroom at https://tinyurl.com/aconnewsroom.
